Thursday November 8, 2012 0 commentsFORT COLLINS - Mike Handley, president of the Northern Colorado Bioscience Cluster, will take over as CEO of CHD Bioscience following the retirement of CEO Ted Ziemann, effective Dec. 1.
Ziemann will remain as CHD's chairman.
Handley has been serving as vice president of regulatory affairs and business development for the company and will retain that role while working closely with Ziemann during the transition.
Ziemann will remain active in investor relations and partnerships as well as his other chairman responsibilities.
Handley has more than 17 years of experience in drug/device commercialization, operations, mergers and acquisitions, regulatory/clinical affairs, venture formation and financing, market development and partnering and licensing.
He has successfully assisted or led in the global commercialization of 17 devices and drugs that have sales revenue of more than $3 billion annually.
Handley is also managing partner and executive director of Level 5 Partners LLC.
CHD Bioscience, located in the Research Innovation Center on the CSU campus, is developing proprietary disinfectant technology with broad applications in therapeutics, medical devices, and surface applications in hospitals, institutions, food manufacturing and preparation, animal health and industry.
For more information, call 970-492-4364 or email [email protected]